Daily Rules, Proposed Rules, and Notices of the Federal Government


Food and Drug Administration

Educational Workshops on Current Good Manufacturing Practices; Public Workshops

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshops.
SUMMARY: The Food and Drug Administration (FDA) is announcing a series of educational workshops on quality pharmaceutical production under current good manufacturing practice (CGMP). The workshops, which will be held in collaboration with the Parenteral Drug Association (PDA), are intended to educate participants on current methods for compliance with good manufacturing practices (GMP). The workshops are being offered to help ensure effective CGMP programs and to further the common goals of FDA and providers of quality pharmaceutical products.
DATES: See table 1 in theSUPPLEMENTARY INFORMATIONsection of this document.
ADDRESSES: See table 1 in theSUPPLEMENTARY INFORMATIONsection of this document.
FOR FURTHER INFORMATION CONTACT: Erik N. Henrikson, Center for Drug Evaluation and Research (HF-18), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-9190,, or Wanda Neal, Parenteral Drug Association, 4350 East West Hwy., suite 200, Bethesda, MD 20814, 301-656-5900, FAX: 301-986-0296,
SUPPLEMENTARY INFORMATION: I. General Information A. Who Should Attend?

This announcement is directed towards professionals involved in the manufacture, control, and regulation of pharmaceutical products who will benefit from these workshops, including process/production engineers, manufacturing personnel, quality assurance/quality control and regulatory affairs professionals, consultants, regulatory investigators, and CGMP compliance officials. Other entities or individuals may also be interested in attending.

B. Where and When Will These Workshops Be Held?

We have scheduled four workshops. The locations and times are listed in table 1 of this document.

Table 1.—Workshop Locations and Schedules Workshop Address Dates and Local Times Hyatt Regency Bethesda, 1 Bethesda Metro Center, Bethesda, MD 20814 November 1 and 2, 2007, from 9 a.m. to 5 p.m. each day The Gresham Hotels, 23 Upper O'Connell St., Dublin 1, Ireland December 10 and 11, 2007, from 9 a.m. to 5 p.m. each day Peking University, Beijing, China 100871 April 21 and 22, 2008, from 9 a.m. to 5 p.m. each day Grand Hyatt Shanghai, Jin Mao Tower, 88 Century Blvd., Pudong, Shanghai, China 200121 April 24 and 25, 2008, from 9 a.m. to 5 p.m. each day C. How Can I Participate?

You can participate in person. Anyone interested in the GMP workshops can register through the contact person (seeFOR FURTHER INFORMATION CONTACT).

D. Is There a Registration Fee for This Workshop?

Yes, a registration fee is required for this workshop. The registration fee includes workshop reference materials and meals. Registration fees for the Bethesda, MD and Dublin, Ireland workshops are listed in table 2 of this document. The registration fee for both China locations (Beijing and Shanghai) is $550 with no discounts. All fees are given in U.S. dollars.

Table 2.—Registration Fees for the Bethesda, MD and Dublin, Ireland Workshops Date of Registration PDA Member Nonmember Government Employee or Health Authority Academic Student Through October 1, 2007 $1,295 $1,695 $350 $3501 $150 After October 1, 2007 $1,495 $1,895 $405 $4051 $180 1Must be PDA member to receive this rate. E. How Can I Get Additional Information?

The notice of participation form, information about the workshops, and other related documents are available from the contact person (seeFOR FURTHER INFORMATION CONTACT) and on the Internet at

II. Background Information A. Why Is FDA Cosponsoring These Workshops?

FDA is cosponsoring these 2-day workshops to provide information and training opportunities for industry as well as CGMP compliance officials.

B. What Will Be Covered?

The workshops will provide information on specific topics designed to educate and guide participants on methodologies and implementation of CGMP as applied to quality drug manufacturing. Presentations by both FDA and industry will provide a regulatory and practical perspective on the current relevant critical topics.

Dated: September 14, 2007. Jeffrey Shuren, Assistant Commissioner for Policy.